Exact Sciences has developed a stool-based screening test that detected 92 percent of cancers found on colonoscopy and 42 percent of precancerous polyps. The results fell shy of the company’s goal of a 50 percent polyp detection rate, according to an article in the New York Times; however, Exact Sciences indicated it plans to file for FDA approval of its Cologuard test.